Fortnightly Review: Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk?
Why the study?
Does the use of short acting dihydropyridine calcium channel blockers pose a risk in patients with hypertension?
Population
Patients with hypertension
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May warrant caution with short-acting dihydropyridines in hypertension; leaves open randomized outcome data versus alternatives.
Structured PICO
Does the use of short acting dihydropyridine calcium channel blockers pose a risk in patients with hypertension?
P
Population
Patients with hypertension
I
Intervention
Short acting dihydropyridine (vasodilating) calcium channel blockers
Highlights the lack of randomized trial evidence for calcium channel blockers and ACE inhibitors in preventing hard clinical endpoints in hypertension, raising safety concerns about short-acting dihydropyridines.
Cite This Study
Beevers et al. (1996) studied this question.